Biosergen is a startup based in Norway, most recent round Series-c-plus, 1 tracked investor.
Biosergen is a startup based in Norway. Its most recent tracked round is Series-c-plus. Brouky records 1 investor associated with the company.
Biosergen is a biotech company developing novel antifungal drugs, with a lead candidate BSG005 (a genetically improved polyene macrolide) aimed at treating invasive fungal infections in immunocompromised patients. The drug was invented in collaboration with NTNU and SINTEF and has completed a Phase 1 study and ongoing proof-of-concept work.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.